By Cody Tranbarger, EIR at Atlas Venture, as part of the From The Trenches feature of LifeSciVC As the biotech industry trudges through its fourth consecutive year of middling performance and sluggish capital markets, corporate governance has become a salient The post A [Prime]r on Stock Option Repricing in Biotech appeared first on LifeSciVC.
